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Abstract
Background: While several molecular markers of bladder cancer prognosis have been identified, the limited value
of current prognostic markers has created the need for new molecular indicators of bladder cancer outcomes. The
aim of this study was to identify genetic signatures associated with disease prognosis in bladder cancer.
Results: We used 272 primary bladder cancer specimens for microarray analysis and real-time reverse transcriptase
polymerase chain reaction (RT-PCR) analysis. Microarray gene expression analysis of randomly selected 165 primary
bladder cancer specimens as an original cohort was carried out. Risk scores were applied to stratify prognosis-
related gene classifiers. Prognosis-related gene classifiers were individually analyzed with tumor invasiveness (non-
muscle invasive bladder cancer [NMIBC] and muscle invasive bladder cancer [MIBC]) and prognosis. We validated
selected gene classifiers using RT-PCR in the original (165) and independent (107) cohorts. Ninety-seven genes
related to disease progression among NMIBC patients were identified by microarray data analysis. Eight genes, a
progression-related gene classifier in NMIBC, were selected for RT-PCR. The progression-related gene classifier in
patients with NMIBC was closely correlated with progression in both original and independent cohorts.
Furthermore, no patient with NMIBC in the good-prognosis signature group experienced cancer progression.
Conclusions: We identified progression-related gene classifier that has strong predictive value for determining
disease outcome in NMIBC. This gene classifier could assist in selecting NMIBC patients who might benefit from
more aggressive therapeutic intervention or surveillance.
Background
Bladder cancer is a genetic disorder driven by the pro-
gressive accumulation of multiple genetic and epigenetic
changes. At the molecular level, these genetic changes
result in uncontrolled cell proliferation, decreased cell
death, invasion, and metastasis. The specific alterations
in gene expression that occur as a result of cross-talk
between various cellular pathways determine the biolo-
gic behavior of the tumor, including growth, recurrence,
progression and metastasis, and may influence patient’s
survival. While several molecular markers for the devel-
opment, recurrence and progression of bladder cancer,
such as p53 and Rb, have been studied [1-3], the limited
value of these established prognostic markers created
the need for new molecular indicators of bladder cancer
outcomes.
New high-throughput microarray technology makes it
possible to gain comprehensive insight into the molecu-
lar basis of human diseases [4,5]. With this technology,
the RNA expression levels of hundreds or even thou-
sands of genes in a tumor can be surveyed simulta-
neously. The use of high throughput technologies to
assess gene expression patterns in tissues, exfoliated
cells in urine, or molecules in serum and in circulating
cells for many malignancies, including bladder cancer,
has been reported [6,7]. These studies open a door to
the possibility of rapidly assessing gene expression pat-
terns in individual tumors to determine tumor classifica-
tion [8], or to predict clinical outcomes [9,10] and
response to chemotherapy [11,12]. In fact, gene
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trials to define populations of patients with breast can-
cer who should receive chemotherapy [10,12]. Such
trials were launched in Dutch academic centers and in
the United States [13].
Many different genetic or epigenetic changes that lead
to aberrant gene expression have been identified in blad-
der cancer [6,7]. Thus, gene expression profiling in blad-
der cancer represents a potentially useful way to
discriminate between good and poor prognosis. Micro-
array gene expression analysis could be used to facilitate
the identification of molecular prognostic markers that
correlate with bladder cancer outcomes. In the current
study, we identified genetic signatures that are asso-
ciated with disease progression in patients with non-
muscle invasive bladder cancer (NMIBC).
Methods
Patients and Tissue Samples
Table 1 shows the baseline characteristics of the case
subjects. We used random computer-generated numbers
to assign specimens from 272 consecutive, histologi-
cally-verified transitional cell carcinomas in primary
bladder cancer patients. To reduce confounding factors
for affecting the analyses, any patients diagnosed with
concomitant carcinoma in situ (CIS) lesion or only CIS
lesion were excluded. For the original cohort, we studied
the frozen specimens of bladder cancer tissue from 165
randomly selected patients who had undergone surgical
resection of a transitional cell carcinoma at the Chung-
buk National University Hospital. The mean follow-up
period for the original cohort was 48 months (median
37 months; range, 1-137 months). To independently
validate our risk-prediction model, 107 randomly
selected primary bladder cancer patients who had simi-
lar clinico-pathological characteristics and had under-
gone surgical resection of a transitional cell carcinoma
at the same hospital were used as an independent
cohort. The mean follow-up period for the independent
cohort was 43 months (median, 26 months; range, 1-
194 months). The study design and validation strategy
are shown in Fig. 1.
All tumors were macro-dissected, typically within 15
minutes of surgical resection. Each bladder cancer speci-
men was confirmed by pathological analysis of a part of
t h et i s s u es a m p l ei nf r e s hf r ozen sections from cystect-
omy and transurethral resection (TUR) specimens, and
then frozen in liquid nitrogen and stored at -80°C until
use. The collection and analysis of all samples was
approved by the Institutional Review Board of Chung-
buk National University, and informed consent was
obtained from each subject.
Tumors were staged and graded according to the stan-
dard criteria [14,15]. In cases of NMIBC, TUR of the
tumor was performed. A second TUR was performed 2-
4 week after the initial resection when it was incomplete
o rw h e nah i g h - g r a d eo rT 1t u m o rw a sd e t e c t e d[ 1 6 ] .
Patients with intermediate- or high-risk NMIBC
received one cycle of intravesical BCG immunotherapy
[16,17]. In cases of muscle invasive bladder cancer
(MIBC), radical cystectomy and complete pelvic lymph
node dissection were performed. Patients with either
pT3 or pT4, or node-positive disease, based on the ana-
lysis of radical cystectomy specimens, received at least 4
Table 1 Baseline Characteristics of Primary Bladder
Cancer Patients
Variables Original
Cohort
(n = 165)
Independent
Cohort
(n = 107)
P
Age - yr (mean) 65.2 ± 12.0 64.1 ± 13.3 0.51*
Gender - no. of patients (%) 0.93
+
Male 135 (81.8) 88 (82.2)
Female 30 (18.2) 19 (17.8)
Grade - no. of patients (%) 0.76
+
Low 105 (63.6) 70 (65.4)
High 60 (36.4) 37 (34.6)
Stage - no. of patients (%) 0.14
+
NMIBC 103 (62.4) 76 (71.0)
Ta 23 (22.3) 21 (27.6)
T1 80 (77.7) 55 (72.4)
MIBC 62 (37.6) 31 (29.0)
T2N0M0 26 (41.9) 8 (25.8)
T3 N0M0 13 (21.0) 8 (25.8)
T4/Any T N+/M+ 23 (37.1) 15 (48.4)
Recurrence - no. of patients
with NMIBC (%)
0.94
+
No 67 (65.0) 49 (64.5)
Yes 36 (35.0) 27 (35.5)
Progression - no. of patients
(%)
NMIBC 0.97
+
No 92 (89.3) 68 (89.5)
Yes 11 (10.7) 8 (10.5)
MIBC 1.00
+
No 42 (67.7) 21 (67.7)
Yes 20 (32.3) 10 (32.3)
Survival - no. of patients with
MIBC (%)
Cancer-specific 0.18
+
Alive 33 (53.2) 21 (67.7)
Deceased 29 (46.8) 10 (32.3)
Overall survival 0.37
+
Alive 28 (45.2) 11 (35.5)
Deceased 34 (54.8) 20 (64.5)
Mean follow-up - months 48.4 42.5 0.25*
Abbreviations: NMIBC, non-muscle invasive bladder cancer; MIBC, muscle
invasive bladder cancer.
* P value was obtained by Student’s t-test.
+ P value was obtained by Pearson chi-square test.
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cally metastatic disease nor non-cystectomy cases were
excluded in this study. Each patient has been followed
and managed according to the standard recommenda-
tion [16-18]. We defined recurrence as the recurrence of
p r i m a r yN M I B Co ft h es a m ep a t h o l o g i cs t a g e ,a n d
defined progression as TNM stage progression after dis-
ease relapse in NMIBC and MIBC.
RNA Extraction
Total RNA was isolated from tissue using the TRIzol
reagent (Life Technologies, NY), according to the manu-
facturer’s protocol. The quality and integrity of the RNA
was confirmed by agarose gel electrophoresis and ethi-
dium bromide staining, followed by visual examination
under ultraviolet light.
Microarray Gene Expression Profiling
Biotin-labeled cRNA for hybridization was prepared
according to Illumina’s recommended sample labeling
procedure. Briefly, 500 ng of total RNA were used for
cDNA synthesis, followed by a coupled amplification/
labeling step (in vitro transcription) to synthesize biotin-
labeled cRNA using the Illumina® TotalPrep RNA
Amplification kit (Ambion Inc., Austin, TX). cRNA con-
centration was measured using RiboGreen (Quant-iT™
RiboGreen® RNA assay kit; Invitrogen-Molecular Probes,
ON, Canada) and a Victor3 spectrophotometer (Perki-
nElmer, CT). cRNA quality was verified by 1% agarose
gel electrophoresis.
Labeled, amplified material (1,500 ng per array) was
hybridized to an Illumina Human-6 BeadChip (48K),
version 2, according to the manufacturer’si n s t r u c t i o n s
(Illumina, Inc., San Diego, CA). Array signals were
developed using Amersham fluorolink streptavidin-Cy3
(GE Healthcare Bio-Sciences, Little Chalfont, UK),
according to the instructions in the BeadChip manual.
Arrays were scanned with an Illumina Bead Array
Reader confocal scanner (BeadStation 500GXDW; Illu-
m i n a ,I n c . ,S a nD i e g o ,C A ) ,a c c o r d i n gt ot h em a n u f a c -
turer’si n s t r u c t i o n s .T h ef u l lm i c r o a r r a yd a t as e ti s
available online http://www.ncbi.nlm.nih.gov/geo/ under
the data series accession number GSE13507.
RT-PCR Analysis
RT-PCR using a Rotor Gene 3000 PCR system (Corbett
Research, Mortlake, Australia) was performed in the ori-
ginal and independent cohorts. GAPDH was analyzed in
parallel as an internal control. RT-PCR reactions con-
taining primers and SYBR Premix EX Taq (Takara Bio
Inc., Otsu, Japan) were carried out in micro-reaction
tubes (Corbett Research). Spectral data were captured
and analyzed using Rotor-Gene Real-Time Analysis
Software 6.0 Build 14 (Corbett Research). Gene expres-
sion was normalized to the expression of GAPDH.
Statistical Analysis
To reduce variation among microarrays, the intensity
values for each microarray were rescaled by means of a
quantile normalization method [19]. Gene expression
values were log2-transformed and median-centered
across samples. A hierarchical clustering algorithm,
using the uncentered correlation coefficient as the mea-
sure of similarity and average linkage clustering, was
applied as described in Eisen et al [20].
To select prognosis-related gene classifiers, individual
analyses were performed based on tumor invasiveness
(NMIBC and MIBC) and prognosis (recurrence, pro-
gression, cancer-specific survival and overall survival).
Univariate Cox regression analysis for microarray was
performed to select genes that correlated significantly
with prognosis. In this analysis, we chose a cutoff
Figure 1 Study design and validation strategies.
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prognosis-related gene signatures, genes in the top 10th
percentile of gene expression ratios for each classifier
were selected for the evaluation of their prognostic
properties in the original cohort.
A patient’s risk score was calculated as the sum of the
levels of expression of each gene multiplied by the cor-
responding regression coefficients [9,16,21-24]. Patients
were classified as having a good-prognosis or poor-prog-
nosis signature, with the 50th percentile (median) of the
risk score as the cutoff value [21,23].
To validate the results, RT-PCR analysis of selected
genes in the original and independent cohorts was car-
ried out. In the original cohort, genes with a Pearson
correlation coefficient of greater than .6 between the
microarray and RT-PCR data were selected for valida-
tion. Prognostic values were determined by the Kaplan-
Meier method, and differences were assessed by log
rank statistics. Statistical analysis was performed in R
(version 2.6.2), and a P value of < 0.05 was considered
statistically significant.
Results
Quality assessment of Gene Expression Profile
We performed microarray analysis of tumor tissue from
165 primary bladder cancer patients followed by unsu-
pervised hierarchical clustering analysis. Tumors with
similar repertoires of gene expression were grouped into
two main clusters without knowledge of tumor class.
The two main clusters exhibited a strong association
with stage (Fig. 2).
Selection of Prognosis-related Gene Classifiers Using
Microarray Gene Expression Profiling
To select prognosis-related genes, a separate analysis was
performed based on invasiveness and prognosis. In uni-
variate Cox regression analysis, 42 genes were correlated
significantly with recurrence and 97 with progression in
NMIBC. Similarly, 44 genes were closely related with
progression, 49 with cancer-specific survival, and 61 sig-
natures with overall survival in MIBC (available at http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507).
To evaluate the prognostic properties of each gene classi-
fier, genes in the top 10th percentile for each classifier
were chosen (total of 30 genes; 4 in recurrence-related
gene classifier and 10 in progression-related gene classi-
fier for NMIBC; 5 in progression-related gene classifier, 5
in cancer-specific survival-related gene classifier and 6 in
overall survival-related gene classifier for MIBC). Risk
scores were calculated for these selected genes, and the
50th percentile (median) value was used as the cutoff for
each classifier to discriminate between good- or poor-
prognosis signature groups [9,21-24].
Patients with NMIBC in the poor-prognosis signature
group had a significantly shorter recurrence time than
those in the good-prognosis signature group (P = 0.009;
Fig. 3A). When we examined progression in NMIBC,
the time to progression was shorter for patients with
poor-prognosis signature than good-prognosis signature.
Furthermore, none of the patients with good-prognosis
signature were associated with progression (P < 0.001;
Fig. 3B). Tumor progression, cancer-specific survival
and overall survival in MIBC were significantly different
between the two groups having good-, and poor-prog-
nosis signatures, respectively (each P < 0.001; Fig. 3C-E).
Validation of Gene Classifiers in the Original Cohort by
RT-PCR
Selected gene classifiers were validated by RT-PCR. Of
the 30 genes analyzed, 14 genes met our selection cri-
teria for validation in the original cohort: 3 in recur-
rence-related gene classifier and 8 in progression-related
gene classifier for NMIBC, and 3 in progression-related
gene classifier for MIBC (Table 2). None of the cancer-
specific and overall survival-related gene classifiers in
Figure 2 Hierarchical cluster analysis of 165 primary bladder
cancers (103 NMIBC and 62 MIBC). Genes with expression values
that had a standard deviation of at least .7 were selected (4,532
genes). The red and green colors reflect high and low expression
levels, respectively.
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.6 between the microarray and RT-PCR results. Thus,
we were unable to validate these genes in the original
cohort.
Patients with good-prognosis signature exhibited an
increased time to recurrence than patients with poor-
prognosis signature in NMIBC, but this difference was
not statistically significant (P = 0.16; Fig. 4A). Analysis
of progression-related gene classifier in NMIBC revealed
significant differences in time to progression between
the good-prognosis and poor-prognosis signature groups
(P < 0.001; Fig. 4B). Notably, for NMIBC, no patient
with good-prognosis signature was associated with dis-
ease progression. Thus, multivariate analysis of disease
progression could not be carried out due to the fact that
none of the patients in the good-prognosis signature
group were associated with progression. Consistent with
t h em i c r o a r r a yd a t af o rp r o g r e s s i o n - r e l a t e dg e n ec l a s s i -
fier in MIBC, the good-prognosis signature group had a
prolonged time to progression as compared to the poor-
prognosis signature group (P < 0.001; Fig 4C).
Independent Validation by RT-PCR
We used RT-PCR to validate prognosis-related gene
classifiers (3 in recurrence-related gene classifier and 8
in progression-related gene classifier for NMIBC and 3
in progression-related gene classifier for MIBC) in an
independent cohort of 107 primary bladder cancer
patients. As with the original cohort, risk scores were
calculated and a median value was used to differentiate
the risk groups. For NMIBC, the good-prognosis signa-
ture group had a significantly increased time to progres-
sion as compared to the poor-prognosis signature group
(P < 0.001; Fig. 5B). As with the original cohort, none of
the patients with good-prognosis signature were
Figure 3 Kaplan-Meier estimations in primary bladder cancer with gene signatures based on microarray analysis of the original
training cohort. Kaplan-Meier curves of (A) recurrence (B) and progression in NMIBC. Kaplan-Meier curves of (C) progression, (D) cancer-specific
survival and (E) overall survival in MIBC.
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related gene classifier in NMIBC and progression-related
gene classifier in MIBC did not uncover any differences
in respective time to recurrence and progression
between good- and poor-prognosis signature groups in
the independent cohort (each P >0.05; Fig. 5A, C).
Discussion
Although there have been reports of the value of gene
expression profiles for cancer prognosis [8-12], only lim-
ited data are available on the prognostic value of
expression profiles in human bladder cancer in relatively
large-scale study populations with long-term follow-up
[25-27]. With regard to the microarray studies that have
been performed in the bladder cancer field to date, San-
chez-Carbayo et al. [25] used cDNA microarrays to facili-
tate the classification scheme of diagnostic and
prognostic utility for stratifying advanced bladder cancer.
This technology allowed them to identify poor outcome
profile could assist in selecting patients who may benefit
from more aggressive therapeutic intervention. Addition-
ally, Dyrskjot et al. [26,27] also reported the clinical use-
fulness of molecular markers for the prediction the
clinical course of patients with NMIBC. These studies
enhance the importance of the genome-wide studies in
bladder cancer fields. In concordance with earlier reports,
our study should support the potential usefulness of
microarray study in these fields [25-27]. However, both
the validity and the reproducibility of microarray-based
clinical research have been challenged [28]. To develop
and validate a method of classification, it is necessary to
start with a sufficiently large set of samples to analyze an
independent test set and a validation set [5]. Further-
more, the results of microarray analysis in general should
be validated using other techniques for quantifying RNA
expression and by an independent cohort to reduce the
false discovery rate [29,30]. In the present study, we used
microarray data to identify several types of prognosis-
related gene classifiers. We were able to validate progres-
sion-related gene classifier in primary NMIBC by
RT-PCR in a relatively large-scale long-term follow-up
independent study population, but not for the other
prognosis-related gene classifiers. These findings empha-
size the importance of validation to support the reliability
of microarray-based results.
The prediction of disease progression for patients with
bladder cancer is a major clinical challenge. A number
Table 2 Correlations Between Microarray Data and RT-
PCR Data for 14 Selected Genes
Prognosis
related-gene
Classifiers
Gene UniGene
Number
Up/
down*
Correlation
+ P
‡
Recurrence
related-gene
classifier in
NMIBC
MGC34830 Hs.502266 Up 0.72 < 0.001
FANCB Hs.554740 Up 0.62 < 0.001
CASP8AP2 Hs.558218 Up 0.66 < 0.001
Progression
related-gene
classifier in
NMIBC
S100A8 Hs.416073 Up 0.85 < 0.001
CELSR3 Hs.631926 Up 0.85 < 0.001
PFKFB4 Hs.476217 Up 0.72 < 0.001
HMOX1 Hs.517581 Up 0.69 < 0.001
MTAP Hs.193268 Down 0.81 < 0.001
MGC17624 Hs.461655 Down 0.68 < 0.001
KIF1A Hs.516802 Up 0.72 < 0.001
COCH Hs.21016 Up 0.78 < 0.001
Progression
related-gene
classifier in MIBC
CDH3 Hs.709226 Up 0.74 < 0.001
DSC3 Hs.41690 Up 0.67 < 0.001
PPP1R14C Hs.486798 Up 0.62 < 0.001
Abbreviations: NMIBC, non-muscle invasive bladder cancer; MIBC muscle
invasive bladder cancer.
* Up-regulated or down-regulated in poor prognosis group.
+ Correlation coefficient for microarray values versus RT-PCR values.
‡ P values for the correlation coefficients were calculated by Pearson
correlation coefficient test.
Figure 4 Kaplan-Meier estimations in primary bladder cancer with gene signatures based on RT-PCR analysis of the original validation
cohort. Kaplan-Meier curves of (A) recurrence and (B) progression in NMIBC, and (C) progression in MIBC.
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to date have been explored as predictors of disease pro-
gression. Some of these, such as p53, have been sug-
gested to be independent markers, while others do not
appear to have a role as prognostic indicators [1-3].
Because multiple genetic alterations are required for the
transformation of a normal cell into a cell with a malig-
nant and ultimately metastatic phenotype, assessment of
multiple markers as a whole might better describe the
biological phenotype of a particular cancer.
We identified the following eight genes as predictors
of progression in patients with NMIBC: S100 calcium
binding protein A8 (S100A8), 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 4 (PFKFB4), heme oxygenase
1 (HMOX1), methylthioadenosine phosphorylase
(MTAP), kinesin family member 1A (KIF1A), coagula-
tion factor C homolog (COCH), EGF LAG seven-pass
G-type receptor 3 (CELSR3) and chromosome 16 open
reading frame 74 (MGC17624). Overexpression of
S100A8 is associated with stage progression, invasion,
metastasis and poor survival in human bladder cancer
[31]. Thus, the expression of S100A8 in NMIBC could
be an early indicator for a sub-group of tumors with a
propensity for muscle invasion. PFKFB4 is strongly
induced by hypoxia through an hypoxia inducible factor
1 alpha (HIF1A) subunit dependent mechanism, and
might contribute significantly to the Warburg effect
observed in malignant gastric, pancreatic, breast and
colon tumors [32,33]. HMOX1 is an essential enzyme in
heme catabolism. HMOX1 participates in the processes
of angiogenesis and vasculogenesis [34]. There are sig-
nificant differences in the distribution of the HMOX1
genotype in patients with different-stage urothelial carci-
noma [35]. MTAP encodes an enzyme that plays a
major role in polyamine metabolism. Many cancers,
including bladder cancer, are deficient of the MTAP
enzyme because the gene is co-deleted along with the
tumor suppressor p16 [36]. KIF1A, a member of the
kinesin family, appears to play a critical role in the
development of axonal neuropathies resulting from
impaired axonal transport [37]. However, the function
of KIF1A related to cancer is unknown. COCH is a cell
adhesion molecule [38]. The specific functions of
CELSR3 and MGC17624 have not been determined.
Although the identification of genes linked to disease
progression suggests potential therapeutic interventions
based on their mechanism of action, the lack of a biolo-
gical context for these genes does not diminish their
potential as clinical biomarkers. Many biomarkers, such
as prostate-specific antigen and carcinoembryonic anti-
gen, have unknown functions but are nonetheless useful
as diagnostic or prognostic markers for disease [5].
Because some genetic events occur early in the disease
process or before progression, molecular diagnosis may
enable the prediction of disease progression before the
onset of symptoms or overt radiographic evidence. Thus,
from a clinical point of view, the most promising applica-
tion for gene classifiers is the early prediction of tumor
progression. In addition, new relevant biomarkers must
provide cost-effective, non-invasive monitoring of low-
risk patients and identify high-risk refractory tumors
before they progress. The main goal of all of these efforts
is to develop more accurate prognostic tools that can be
used to direct treatment [5]. In the current study, we
identified a specific subset of genes that predicted pro-
gression in NMIBC. NMIBC is a heterogeneous group
including patients with the enormous array of clinical
and pathological risk factors involved, such as number of
tumors, tumor size, prior recurrence rate, T-category,
carcinoma in situ, grade, intravesical therapy, and other
Figure 5 Kaplan-Meier estimations in primary bla d d e rc a n c e rw i t hg e n es i g n a t u r e sb a s e don RT-PCR analysis of the independent
validation cohort. Kaplan-Meier curves of (A) recurrence and (B) progression in NMIBC, and (C) progression in MIBC.
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these factors needs to control confounding effects. How-
ever, in the present study, multivariate analysis of disease
progression could not be carried out due to the fact that
any patients with NMIBC in the good-prognosis signa-
ture group did not experience cancer progression. None-
theless, this gene set of progression-related markers has
favorable potential to contribute to the understanding of
bladder cancer behavior and the future treatment of
patients with urothelial cancer.
Conclusions
The progression-related gene classifier identified in the
current study represents a potentially valuable tool for
the stratification of heterogeneous bladder cancer
patient populations into risk groups that can be used to
guide clinical decision-making, including observation
versus adjuvant therapy. We derived clear clinical results
using gene classifier for progression in NMIBC. The
results of the current study suggest that the gene
expression profiling to determine progression can be
used to provide customized clinical care.
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